Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;25(3):552-560.
doi: 10.1016/j.drudis.2019.12.003. Epub 2019 Dec 13.

Comparison of DNA and mRNA vaccines against cancer

Affiliations
Review

Comparison of DNA and mRNA vaccines against cancer

Zohreh Jahanafrooz et al. Drug Discov Today. 2020 Mar.

Abstract

Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

M.R.H. declares the following potential conflicts of interest. Scientific Advisory Boards: Transdermal Cap Inc; BeWell Global Inc.; Hologenix Inc.; LumiThera Inc.; Vielight; Bright Photomedicine; Quantum Dynamics LLC; Global Photon Inc.; Medical Coherence; NeuroThera; JOOVV Inc.; AIRx Medical; FIR Industries, Inc.; UVLRx Therapeutics; Ultralux UV Inc.; Illumiheal & Petthera; MB Lasertherapy; ARRC LED; Varuna Biomedical Corp.; and Niraxx Light Therapeutics, Inc. Consulting: Lexington Int.; USHIO Corp.; Merck KGaA; Philips Electronics Nederland; Johnson & Johnson Inc.; and Sanofi-Aventis Deutschland GmbH. Stockholdings: Global Photon Inc. and Mitonix.

Figures

Figure 1.
Figure 1.
The production and function of naked DNA and mRNA vaccines. After determining the sequences of suitable tumor antigens (TAs), the required DNA or mRNA backbone is used in both types of vaccine. For DNA vaccines, amplification is performed in a suitable host cell, such as bacteria, and, after transfection of the purified DNA plasmid, transcription and translation are performed in the nucleus and cytoplasm of the host target cell, respectively (right side). For mRNA vaccines, T7 RNA polymerase is commonly used to amplify the mRNA vaccine in vitro, leaving only translation of TAs to be carried out after transfection (left side). The intracellular TA protein can be proteasomally degraded and routed to the endoplasmic reticulum, where antigenic peptide epitopes (square and sphere shapes) are loaded onto major histocompatibility complex (MHC) I and then presented to CD8+ T cells. Extracellular TAs can be taken up by endocytosis and loaded onto MHC II for presentation to helper T cells. Antigen-presenting cells (APCs), such as dendritic cells (DCs), can present antigens (endogenous and exogenous) on both MHC I and MHC II. Most other cells present antigens only on MHC I. Abbreviations: ORF, open reading frame; UTR, untranslated region.

References

    1. Chakraborty C et al. (2018) The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. Oncotarget 9 10164–10174 - PMC - PubMed
    1. Sathyanarayanan V and Neelapu SS (2015) Cancer immunotherapy: strategies for personalization and combinatorial approaches. Mol. Oncol 9, 2043–2053 - PMC - PubMed
    1. Ventola CL (2017) Cancer immunotherapy, Part 1: current strategies and agents. P. T 42, 375–83 - PMC - PubMed
    1. Guo C et al. (2013) Therapeutic cancer vaccines: past, present, and future. Adv. Cancer Res 119, 421–475 - PMC - PubMed
    1. Rezaei T et al. (2019) Recent advances on HIV DNA vaccines development: stepwise improvements to clinical trials. J. Control. Release 316, 116–137 - PubMed

Publication types

MeSH terms